Compare Organon & Co. Common Stock (OGN) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Visa Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Visa Inc trades at $394.88 (market cap $734.85B). The key difference: Visa Inc is far larger — about 203× Organon & Co. Common Stock's market cap, and Visa Inc pays the higher dividend (0.68%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Visa Inc for 115 Days on average.
| OGN | V | |
|---|---|---|
Market Cap | $3.62B | $734.85B |
Volume | 2,892,999 | 7,725,378 |
Sector | Health | Financials |
52-Week High | $13.81 | $396.06 |
52-Week Low | $5.70 | $295.52 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $11.04B | $745.43B |
Dividend Yield | 0.58% | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Visa (V) trades at $396.06, up 1.74% today, near its 52-week high. The stock shows strong technical momentum with bullish moving averages and key resistance at $399. Fundamentally, Visa reported robust earnings beats in recent quarters, with Q2 2026 results due April 28. Revenue grew to $40B in 2025, with a net income margin of 50.78%, though the P/E ratio of 33.71 is elevated. Recent news highlights Visa's push into AI-driven commerce and stablecoin partnerships.
Outlook remains positive with 85% analyst buy ratings and a $423.29 consensus target, implying 7% upside. Risks include competitive fintech threats and regulatory scrutiny. Strong cash flow and institutional accumulation support long-term growth, but high valuation requires sustained execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
